Safety of tralokinumab in pediatric patients aged 12-17 years with moderate to severe atopic dermatitis: results from the phase 3 ECZTRA 6 trial. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s140. https://doi.org/10.25251/skin.7.supp.140